Compare Stocks › ABBV vs CHRW

AbbVie Inc. (ABBV) vs C.H. Robinson Worldwide, Inc. (CHRW): Which Is the Better Buy in 2026?

As of 2026-11-01, ABBV is overvalued at $295, with a DCF intrinsic value of $172 and a margin of safety of -71%. CHRW is undervalued at $125, with an intrinsic value of $185 and a margin of safety of 33%. Of the two, CHRW has the wider margin of safety.

ABBV
AbbVie Inc.
$294.89
VS
CHRW
C.H. Robinson Worldwide, Inc.
$124.61

Rewards

ABBV
  • ★AbbVie Inc. has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
  • ★Gross margin of 73.7% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • ★AbbVie Inc. scores 82/100 on the Economic Moat Score (Wide Moat), with reinvestment efficiency as the strongest competitive dimension.
CHRW
  • ★C.H. Robinson Worldwide, Inc. has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
  • ★Return on equity has consistently exceeded 20% over 4 years, indicating efficient use of shareholder capital.
  • ★Market sentiment is in extreme fear territory (score: 22/100) — historically, periods of fear have often presented buying opportunities.

Risks

ABBV
  • ⚠Buybacks have been poorly timed — 3 out of 4 years involved repurchases at relatively expensive valuations.
  • ⚠Insiders have sold $8.2M worth of stock in the past 3 months — significant insider liquidation.
  • ⚠Free cash flow has declined at a 9.8% CAGR over the past 4 years — a concerning trend.
CHRW
  • ⚠Gross margin of 8.3% is low, suggesting a competitive or commodity-like market with limited pricing power.
  • ⚠Buybacks have been poorly timed — 2 out of 3 years involved repurchases at relatively expensive valuations.
  • ⚠FCF yield of 5.8% suggests reasonable valuation assuming continued moderate growth.

Key Valuation Metrics

Learn more →
ABBV
CHRW
Valuation
N/A
Free Cash Flow
$843.98M
N/A
FCF Yield
5.84%
50.67
Trailing P/E
22.37
18.24
Forward P/E
16.70
Quality & Moat
29.08%
ROIC
21.83%
N/A
ROE
38.92%
73.72%
Gross Margin
8.35%
0.60
PEG Ratio
1.49
Balance Sheet Safety
N/A
Net Debt / Equity
1.24
N/A
Interest Coverage
N/A
2.03
Net Debt / EBITDA
1.95
2.35%
Dividend Yield
2.02%
ABBV: 4Ties: 2CHRW: 2
ABBVCHRW

Historical Fundamentals

Learn more →
ABBV

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

CHRW

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

$1 Retained Earnings Test

Learn more →
ABBV
N/A
Net losses over 3 years — test not applicable
Company had negative cumulative retained earnings
Σ Retained
$-19.85B
Δ Market Cap
+$118.02B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
CHRW
$17.11
created per $1 retained over 3 years
Exceptional Value Creator
Σ Retained
$490.2M
Δ Market Cap
+$8.39B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Discounted Cash Flow (DCF) Analysis

Learn more →
ABBV
71.5% Overvalued
Price is 71.5% above estimated fair value
Current Price: $294.89
Fair Value: $172.00
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
CHRW
32.7% Margin of Safety
Price is 32.7% below estimated fair value
Current Price: $124.61
Fair Value: $185.06
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued

Reverse DCF — Market-Implied Growth

Learn more →
ABBV

Requires positive FCF to compute implied growth rate.

CHRW

What growth rate is the market pricing in at $125?

+11.5%
Market-Implied Owner Earnings Growth
Standard FCF implies +7.3%

The market implies +11.5% Owner Earnings growth, above historical trends.

Standard FCF implies a demanding +7.3%, reflecting heavy growth investment.

Economic Moat Score

Learn more →
ABBV
82/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. Reinvestment Efficiency is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
CHRW
61/100
Narrow Moat
70+ Wide · 40-69 Narrow · <40 None

Narrow moat with roic consistency as the key competitive advantage. Improving revenue predictability would strengthen the moat.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

Forensic Accounting

Learn more →
ABBV
-2.86
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
CHRW
-2.79
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Ownership Breakdown

Learn more →
ABBV
Insiders 0.1%Institutions 77.4%Retail & Other 22.5%
No. of Institutional Holders5,303
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
CHRW
Insiders 0.4%Institutions 106.1%
No. of Institutional Holders1,253
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

Insider Buying Activity

Learn more →
ABBV
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises
CHRW
0
Buys (3M)
3
Buys (12M)
Total value (12M): $400,535
BOZEMAN DAVID P
Chief Executive Officer
$199,771
@ $163.35 · 2026-02-12
CASTAGNETTO MICHAEL DAMIEN
Officer
$100,000
@ $168.35 · 2026-02-12
LEE DAMON J.
Chief Financial Officer
$100,764
@ $162.52 · 2026-02-12
Open market purchases · includes direct & indirect ownership · excludes option exercises

Open market purchases · includes direct & indirect ownership · excludes option exercises.

Insider Selling Activity

Learn more →
ABBV
1
Sells (3M)
4
Sells (12M)
Total value (12M): $18.92M
DONOGHOE NICHOLAS
Officer
$8.18M
@ $250.00 · 2026-08-14
PURDUE DAVID RYAN
Officer
$1.22M
@ $233.56 · 2026-03-04
SIATIS PERRY C.
General Counsel
$4.38M
@ $234.39 · 2026-03-02
SIATIS PERRY C.
General Counsel
$5.15M
@ $230.00 · 2026-02-25
SALEKI-GERHARDT AZITA
Chief Operating Officer
$8.41M
@ $198.42 · 2025-08-12
DONOGHOE NICHOLAS
Officer
$2.64M
@ $198.51 · 2025-08-05
STEWART JEFFREY RYAN
Officer
$12.36M
@ $210.08 · 2025-03-31
REENTS SCOTT T.
Chief Financial Officer
$3.75M
@ $212.34 · 2025-03-14
GONZALEZ RICHARD A
Director
$20.26M
@ $205.45 · 2025-03-03
RICHMOND TIMOTHY J
Officer
$4.47M
@ $210.45 · 2025-03-03
SIATIS PERRY C.
General Counsel
$5.82M
@ $208.69 · 2025-03-03
RICHMOND TIMOTHY J
Officer
$6.07M
@ $202.90 · 2025-02-26
BUCKBEE KEVIN K
Officer
$3.85M
@ $203.41 · 2025-02-26
SIATIS PERRY C.
General Counsel
$1.14M
@ $197.90 · 2025-02-20
BUCKBEE KEVIN K
Officer
$310,032
@ $172.24 · 2024-12-16
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
CHRW
0
Sells (3M)
8
Sells (12M)
Total value (12M): $18.87M
FREEMAN ANGELA K.
Officer
$1.72M
@ $200.52 · 2026-02-09
SHORT MICHAEL JOHN
Officer
$1.28M
@ $201.30 · 2026-02-09
CASTAGNETTO MICHAEL DAMIEN
Officer
$553,276
@ $194.20 · 2026-02-02
SHORT MICHAEL JOHN
Officer
$215,250
@ $175.00 · 2026-01-15
SHORT MICHAEL JOHN
Officer
$386,965
@ $161.91 · 2025-12-31
RAJAN ARUN
Officer
$381,925
@ $152.77 · 2025-11-17
FREEMAN ANGELA K.
Officer
$7.47M
@ $149.71 · 2025-11-06
CASTAGNETTO MICHAEL DAMIEN
Officer
$6.87M
@ $151.70 · 2025-11-03
RAJAN ARUN
Officer
$304,350
@ $121.74 · 2025-08-15
FREEMAN ANGELA K.
Officer
$664,096
@ $116.24 · 2025-08-11
SHORT MICHAEL JOHN
Officer
$746,125
@ $117.24 · 2025-08-06
FREEMAN ANGELA K.
Officer
$555,322
@ $97.42 · 2025-05-14
FREEMAN ANGELA K.
Officer
$803,120
@ $100.39 · 2025-02-27
CASTAGNETTO MICHAEL DAMIEN
Officer
$499,594
@ $99.60 · 2025-02-18
SHORT MICHAEL JOHN
Officer
$1.22M
@ $99.58 · 2025-02-18
CASTAGNETTO MICHAEL DAMIEN
Officer
$210,942
@ $103.81 · 2024-12-31
CAMPBELL BEN G
Officer
$2.86M
@ $110.00 · 2024-12-11
SHORT MICHAEL JOHN
Officer
$1.14M
@ $109.87 · 2024-11-11
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

🎭 Mr. Market's Mood

Learn more →
ABBV
FearGreed
😏Greed(72/100)

"Market is optimistic — be cautious and ensure you have a margin of safety"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
CHRW
FearGreed
😨Fear(22/100)

"Market is pessimistic — investigate whether fears are temporary or structural"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

⚖️ Buffett Signal

Learn more →
ABBV
⚪Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Greed (72)
CHRW
⚪Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Fear (22)
View ABBV Full AnalysisView CHRW Full Analysis

Frequently Asked Questions: ABBV vs CHRW

Is AbbVie Inc. or C.H. Robinson Worldwide, Inc. more undervalued in 2026?▼

Based on our discounted cash flow model, CHRW trades at a 32.7% margin of safety (intrinsic value $185 vs. price $125), compared to ABBV's -71.5% margin of safety (intrinsic $172 vs. $295).

Which stock has a wider economic moat, AbbVie Inc. or C.H. Robinson Worldwide, Inc.?▼

ABBV scores 82/100 (Wide moat), while CHRW scores 61/100 (Narrow moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

Is AbbVie Inc. in financial distress?▼

ABBV's Altman Z-Score of 2.4 places it in the Grey zone, signaling elevated bankruptcy risk. CHRW scores 9.2 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

Which stock has higher return on invested capital, AbbVie Inc. or C.H. Robinson Worldwide, Inc.?▼

ABBV earns 29.1% ROIC versus CHRW's 21.8%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

Which dividend is safer, AbbVie Inc.'s or C.H. Robinson Worldwide, Inc.'s?▼

CHRW's dividend earns a safety score of 78/100 (Safe), compared to ABBV's 39/100 (Unsafe). CHRW has raised its dividend for 1 consecutive years.

ABBV vs CHRW: Which Is the Better Buy in 2026? | SafetyMargin.io